Business Wire Industry News

Thursday, January 26, 2023

Devonian Health Group Announces its Participation at BIO CEO & Investor Conference

QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that Mr. Pierre Montanaro, President and Chief Executive Officer of the Corporation, is scheduled to present at the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on Februar

Thursday, January 26, 2023

Cybin to Host Virtual R&D Day on February 28, 2023

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics® today announced that it will host a virtual R&D Day on Tuesday, February 28, 2023, from 10:00 a.m. ET to 11:30 a.m. ET. The event, which will be hosted by Cybin’s leadership team, will provide a progress update on the Company’s development pipeline of differentiated psychedelic-based therapeutics, including CYB003 and

Wednesday, January 25, 2023

Wellbeing Digital to Participate in the Psychedelic Medicine Association Webinar

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $KONEF #psychedelics--Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO of Wellbeing, will participate at the upcoming Psychedelic Medicine Association (PMA) Webinar on Thursda

Wednesday, January 25, 2023

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Guggenheim Oncology Conference 2023. Zymeworks’ management will participate in one-on-one meetings on February 8th – 9th and a fireside chat on February 9th at 2:10 pm Eastern Time (ET) in New York, NY. SVB Securities Global Biopharma

Tuesday, January 24, 2023

Inversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference

MONTREAL--(BUSINESS WIRE)-- #CB1--Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma Conference being held January 31 through February 2, 2023. For additional information or to request a

Tuesday, January 24, 2023

Gandeeva Therapeutics Announces Appointment of Dr. Brenda G. Cooperstone to its Board of Directors

VANCOUVER, British Columbia--(BUSINESS WIRE)--Gandeeva Therapeutics, Inc., a biotechnology company focused on designing and developing precision therapeutics guided by cryogenic electron microscopy (cryo-EM) and machine learning, announced today the appointment of Brenda G. Cooperstone, MD, as an independent member of its Board of Directors. Dr. Cooperstone is a pharmaceutical executive with more than 20 years of experience in drug development. She most recently served as the Chief Development

Monday, January 23, 2023

The Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital selects Cubresa’s BrainPET Insert System to support brain research studies

WINNIPEG, Manitoba--(BUSINESS WIRE)-- #Cubresa--The Martinos Center has selected Cubresa’s investigational BrainPET System to add to their suite of imaging tools. The Cubresa BrainPET Insert System will benefit the research efforts of ongoing projects focused on several neurological disorders and related topics including, anxiety disorders, autism spectrum disorder, bipolar disorder, depression, HIV/AIDS and mental health, schizophrenia, substance use, traumatic events, as well as neurological diseases an